Theranostic Approach to Asthma Using Anti-Angiogenic Nanomedicine

使用抗血管生成纳米药物治疗哮喘的方法

基本信息

批准号：
8618918
负责人：
Gregory M Lanza
金额：
$ 66万
依托单位：
WASHINGTON UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2012
资助国家：
美国
起止时间：
2012-04-09 至 2017-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8618918
关键词：
Acute Adult Affect American Angiogenesis Inhibitors Asthma Atherosclerosis Basement membrane Blood Volume Blood flow Caring Chronic Collaborations Development Disease Doctor of Philosophy Dose Economic Burden Edema Elements Fluorocarbons Glucocorticoids Health Care Costs Healthcare Systems Histopathology Home Care Services Hospitalization Hyperplasia Image Infiltration Inflammatory Lipase Lung Lung diseases Malignant Neoplasms Modeling Molecular Molecular Biology Pathologic Patients Pharmaceutical Preparations Pharmacodynamics Phospholipids Physiology Pre-Clinical Model Prodrugs Rattus norvegicus Research Respiratory physiology Role Severities Smooth Muscle Staging Steroids Stratification Structure Symptoms Therapeutic Agents airway epithelium airway inflammation airway obstruction airway remodeling angiogenesis antiangiogenesis therapy base density design eosinophil experience fumagillin functional status hemodynamics improved lung development molecular imaging nanomedicine nanoparticle nanotherapy novel professor pulmonary function respiratory response to injury spatiotemporal standard of care theranostics

项目摘要

DESCRIPTION (provided by applicant): Asthma is a chronic inflammatory lung disease that affects an estimated 23 million Americans (16 million adults), 12 million of whom experience at least one asthma attack annually. The symptoms of asthma cause significant economic burden on the healthcare systems ($18B in 2008) as well as dramatic impact on the quality of patients' lives. Asthma is characterized by airway inflammation and edema. Recently, the long recognized increase in airway wall microvessel density and expanded blood volume have been suggested to contribute significantly to lung function. This project combines the recognized expertise of Professor Elizabeth Wagner, PhD (PI) in pulmonary angiogenesis physiology and Professor Gregory M. Lanza, MD PhD (PD/PI), whose nanomedicine-based molecular imaging and therapy is well known, particularly in the context of angiogenesis in cancer and atherosclerosis. The overarching hypotheses of this proposal are to use nanomedicine approach to noninvasively characterize bronchial angiogenesis (new vessel formation), to deliver acute antiangiogenic therapy to reduce airway remodeling and improve pulmonary function, and to maintain the acute benefits of this new treatment with standard-of-care low dose steroids.

描述（由申请人提供）：哮喘是一种慢性炎症性肺部疾病，影响估计 2300 万美国人（1600 万成年人），其中 1200 万人每年至少经历一次哮喘发作。哮喘症状给医疗保健系统造成重大经济负担（2008 年为 $18B），并对患者的生活质量产生巨大影响。哮喘的特征是气道炎症和水肿。最近，人们早已认识到气道壁微血管密度的增加和血容量的扩大对肺功能有显着贡献。该项目结合了Elizabeth Wagner教授（PI）在肺血管生成生理学方面的公认专业知识和Gregory M. Lanza教授（医学博士博士（PD/PI）），他们基于纳米医学的分子成像和治疗是众所周知的，特别是在背景下癌症和动脉粥样硬化中的血管生成。该提案的总体假设是使用纳米医学方法非侵入性地表征支气管血管生成（新血管形成），提供急性抗血管生成治疗以减少气道重塑并改善肺功能，并以标准的标准维持这种新治疗的急性益处。 -护理低剂量类固醇。